Stay updated on SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Sign up to get notified when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.

Latest updates to the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision updated to v3.4.2 from v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 with no visible changes to study content, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check33 days agoChange DetectedGlossary UI options (Show glossary / Hide glossary) were added. Metadata lines were updated to include Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, while the older QC-related entry and Revision: v3.3.4 were removed.SummaryDifference0.4%

- Check40 days agoChange DetectedAdded Revision: v3.3.4; Deleted Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check68 days agoChange DetectedAdded a footer note 'Revision: v3.3.3'; removed 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' from the footer.SummaryDifference0.1%

- Check90 days agoChange DetectedThe page revision updated from v3.2.0 to v3.3.2 (metadata) and no substantive study content changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SMT-NK with Pembrolizumab in Biliary Tract Cancer Clinical Trial page.